Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyl Alcohol SCHEMBL8042983 | 0.90 | LMNA (0.60) | LMNAALDH1A1THRBSMN1; SMN2HSD17B10 | |
| Ethylene Glycol SCHEMBL356222 | 0.88 | LMNA (0.75) | LMNAALDH1A1THRBTSHR | |
| SCHEMBL10434124 | 0.87 | LMNA (0.57) | LMNAALDH1A1THRBSMN1; SMN2HSD17B10 | |
| Propanol SCHEMBL8131034 | 0.86 | LMNA (0.71) | LMNAALDH1A1THRBSMN1; SMN2HSD17B10 | |
| Octanol SCHEMBL6324775 | 0.85 | LMNA (0.59) | LMNAALDH1A1THRBSMN1; SMN2HSD17B10 | |
| Alcohol SCHEMBL1490179 | 0.85 | LMNA (0.80) | LMNAALDH1A1THRBTSHR | |
| Methyl Alcohol SCHEMBL5434659 | 0.82 | LMNA (0.86) | LMNATHRBTSHR | |
| SCHEMBL9459 | 0.82 | — | — | |
| SCHEMBL2094168 | 0.82 | LMNA (1.00) | LMNATHRB | |
| Ethylene Glycol SCHEMBL9004515 | 0.81 | LMNA (0.63) | LMNAALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172560-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2020-06-04 | — | — | US | disclosed |
| WO-2018224923-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-12-13 | — | — | WO | disclosed |
| EP-2537839-B1 | B-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING B-DIHYDROFURAN DERIVING COMPOUND OR B-TETRAHYDROFURAN DERIVING COMPOUND, B -GLYCOSIDE COMPOUND, METHOD FOR PRODUCING B-GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2016-12-14 | — | — | EP | disclosed |
| US-9212174-B2 | Certain β-dihydrofuran derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-2537851-B1 | PROCESS FOR PREPARATION OF B-GLYCOSIDE COMPOUNDS | NISSAN CHEMICAL IND LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8975394-B2 | Process for preparation of β-glycoside compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| EP-2537839-A1 | B-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING B-DIHYDROFURAN DERIVING COMPOUND OR B-TETRAHYDROFURAN DERIVING COMPOUND, B -GLYCOSIDE COMPOUND, METHOD FOR PRODUCING B-GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-2537851-A1 | PROCESS FOR PREPARATION OF B-GLYCOSIDE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322995-A1 | beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120309958-A1 | PROCESS FOR PREPARATION OF B-GLYCOSIDE COMPOUNDS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | G.D. SEARLE LLC | 2002-03-14 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001068637-A2 | METHOD FOR THE PREPARATION OF TETRAHYDROBENZOTHIEPINES | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | LMNA 3965/4885ALDH1A1 852/4885THRB 1065/4885 |
| US-20200172560-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | CFB, F13B, C9 | LMNA 1530/4885ALDH1A1 4153/4885THRB 4338/4885 |
| US-20020032329-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | LMNA 3289/4885ALDH1A1 44/4885THRB 1182/4885 |
| US-20120322995-A1 | beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | DHPS, B4GALT1, STT3A | LMNA 1640/4885ALDH1A1 495/4885THRB 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.